暖宫七味丸联合头孢地尼治疗慢性盆腔炎的疗效观察

目的探讨暖宫七味丸联合头孢地尼治疗慢性盆腔炎的临床效果。方法选取2017年10月—2018年10月西安医学院第二附属医院收治的86例慢性盆腔炎患者,随机分为对照组和治疗组,每组各43例。对照组口服头孢地尼胶囊,1粒/次,3次/d。治疗组在对照组基础上口服暖宫七味丸,11丸/次,2次/d。两组均连续治疗14 d。观察两组的临床疗效,比较两组治疗前后主要症状和体征积分、盆腔包块直径和输卵管直径变化情况。比较两组不良反应发生率和复发情况。结果对照组和治疗组的总有效率分别是81.4%、95.3%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者下腹胀痛或刺痛评分、腰骶胀痛评分、带下异常评分、子宫活动受限评分、附件增厚/包块评分、宫骶韧带增粗、触痛评分均显著低于治疗前,同组治疗前后比较差异有统计学意义(P0.05);治疗后,治疗组这些主要症状、体征评分均显著低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组盆腔包块直径和输卵管直径均较治疗前显著缩小,同组治疗前后比较差异有统计学意义(P0.05);治疗后,治疗组盆腔包块直径和输卵管直径显著小于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,对照组和治疗组的不良反应发生率是2.3%、4.7%,两组比较差异没有统计学意义。停药6个月内,对照组和治疗组的复发率分别是25.6%、9.3%,两组比较差异具有统计学意义(P0.05)。结论暖宫七味丸联合头孢地尼治疗慢性盆腔炎具有较好的临床疗效,能有效减轻患者的临床症状及体征评分,降低复发风险,具有一定的临床推广应用价值。

Clinical study on Wengong Qiwei Pills combined with cefdinir in treatment of chronic pelvic inflammatory disease

Objective To investigate the clinical effect of Wengong Qiwei Pills combined with cefdinir in treatment of chronic pelvic inflammatory disease. Methods Patients (86 cases) with chronic pelvic inflammatory disease in Second Affiliated Hospital of Xi''an Medical College from October 2017 to October 2018 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were po administered with Cefdinir Capsules, 1 grain/time, three times daily. Patients in the treatment group were po administered with Wengong Qiwei Pills on the basis of the control group, 11 pills/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the changes of main symptom and sign scores, pelvic mass diameter and fallopian tube diameter before and after treatment were compared between the two groups. The incidence of adverse reactions and recurrence were compared between the two groups. Results After treatment, the clinical efficacy in the control and treatment groups were 81.4% and 95.3%, respectively, and there were differences between two groups (P<0.05). After treatment, lower abdominal distension or tingling pain scores, lumbosacral distension scores, subband abnormality scores, uterine activity limitation scores, adnexal thickening/mass scores, uterine sacral ligament thickening scores, and tenderness scores in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, those main symptoms and signs scores in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, pelvic mass diameter and tubal diameter in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, pelvic mass diameter and tubal diameter in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, the adverse reaction rate in the control and treatment groups were 2.3% and 4.7%, respectively, and there was on differences between two groups (P<0.05). Discontinuation within 6 months, the recurrence in the control and treatment groups were 25.6% and 9.3%, respectively, and there were differences between two groups (P<0.05). Conclusion Wengong Qiwei Pills combined with cefdinir has good clinical effect in treatment of chronic pelvic inflammatory disease, and can effectively reduce patients'' clinical symptoms and signs score, and also can reduce the risk of recurrence, which has a certain clinical application value.